{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-096071","form_type":"8-K/A","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2025-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.494512+00:00","generated_at":"2026-05-17T04:55:21.282685+00:00","sec_items":["2.05","5.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"confidence":"high","headline":"KALA halts pipeline, cuts 51% of staff, grants retention bonuses to top executives","bullets":["Ceased development of KPI-012 and stem cell platform; workforce reduced by ~19 employees (~51%).","Expects ~$0.4M in restructuring costs (severance/benefits), substantially in Q4 2025.","Entered retention agreements: CEO Todd Bazemore ($183,750), CFO Mary Reumuth ($136,250), CMO Kim Brazzell ($145,000).","Company preserving cash while exploring strategic alternatives."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-096071","json":"https://secwatch.observer/filing/0001104659-25-096071.json","markdown":"https://secwatch.observer/filing/0001104659-25-096071.md","text":"https://secwatch.observer/filing/0001104659-25-096071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000110465925096071/0001104659-25-096071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000110465925096071/tm2527808d1_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:55:21.282685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}